Helius Medical Technologies Inc Class A (HSDT)vsJPMorgan Chase & Co (JPM)
HSDT
Helius Medical Technologies Inc Class A
$2.29
+2.69%
FINANCIAL SERVICES · Cap: $147.14M
JPM
JPMorgan Chase & Co
$343.54
+1.26%
FINANCIAL SERVICES · Cap: $902.16B
Smart Verdict
WallStSmart Research — data-driven comparison
JPMorgan Chase & Co generates 1579862% more annual revenue ($190.73B vs $12.07M). JPM leads profitability with a 34.6% profit margin vs 0.0%. HSDT trades at a lower P/E of 0.0x. JPM earns a higher WallStSmart Score of 71/100 (B).
HSDT
Avoid32
out of 100
Grade: F
JPM
Strong Buy71
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 5774.0% year-over-year
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 42.6%
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -137.4% — below average capital efficiency
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HSDT
The strongest argument for HSDT centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 5774.0% demonstrates continued momentum.
Bull Case : JPM
The strongest argument for JPM centers on Market Cap, Profit Margin, Operating Margin. Profitability is solid with margins at 34.6% and operating margin at 42.6%. Revenue growth of 10.2% demonstrates continued momentum.
Bear Case : HSDT
The primary concerns for HSDT are EPS Growth, Market Cap, Profit Margin.
Bear Case : JPM
The primary concerns for JPM are PEG Ratio, Altman Z-Score, Debt/Equity. Debt-to-equity of 3.32 is elevated, increasing financial risk.
Key Dynamics to Monitor
HSDT profiles as a hypergrowth stock while JPM is a mature play — different risk/reward profiles.
HSDT carries more volatility with a beta of 1.12 — expect wider price swings.
HSDT is growing revenue faster at 5774.0% — sustainability is the question.
Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JPM scores higher overall (71/100 vs 32/100), backed by strong 34.6% margins and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Helius Medical Technologies Inc Class A
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing and acquiring non-invasive technologies for the treatment of symptoms caused by neurological diseases or trauma. The company is headquartered in Newtown, Pennsylvania.
JPMorgan Chase & Co
FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA
JPMorgan Chase & Co. is an American multinational investment bank and financial services holding company headquartered in New York City. JPMorgan Chase is incorporated in Delaware. As a Bulge Bracket bank, it is a major provider of various investment banking and financial services. It is one of America's Big Four banks, along with Bank of America, Citigroup, and Wells Fargo. JPMorgan Chase is considered to be a universal bank and a custodian bank. The J.P. Morgan brand is used by the investment banking, asset management, private banking, private wealth management, and treasury services divisions.
Visit Website →Compare with Other ASSET MANAGEMENT Stocks
Want to dig deeper into these stocks?